NASDAQ:ANAB AnaptysBio Q1 2027 Earnings Results & Report $47.77 -1.00 (-2.05%) Closing price 04:00 PM EasternExtended Trading$47.40 -0.37 (-0.78%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. AnaptysBio beat analyst expectations on both earnings and revenue in its Q1 2027 results, released November 12, 2026. The company reported EPS of $0.11 versus the -$1.84 consensus estimate, while revenue of $30.27 million topped the $25.56 million estimate by $4.72 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2027Report DateNovember 12, 2026TimeAfter Market ClosesConference Call4:00 PM ET AnaptysBio EPS ResultsActual EPS$0.11Consensus EPS -$1.84Beat/MissBeat by +$1.95One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersAnaptysBio Revenue ResultsActual Revenue$30.27 millionExpected Revenue$25.56 millionBeat/MissBeat by +$4.72 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) AnaptysBio Q1 2027 Earnings FAQ Did AnaptysBio beat earnings estimates for Q1 2027? AnaptysBio (NASDAQ:ANAB) reported earnings of $0.11 per share for Q1 2027, beating the consensus estimate of -$1.84. The report was announced on Thursday, November 12, 2026. What was AnaptysBio's revenue for Q1 2027? AnaptysBio reported revenue of $30.27 million for Q1 2027, against a consensus estimate of $25.56 million. AnaptysBio Earnings HeadlinesAnaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update31 minutes ago | globenewswire.comAnaptysBio, Inc. (ANAB) - What Are Analysts Thinking About This Stock?November 12 at 2:28 AM | americanbankingnews.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 12 at 1:00 AM | Behind the Markets (Ad)Anaptys Announces Participation in Upcoming Investor ConferencesNovember 10 at 4:20 PM | globenewswire.comHead to Head Survey: AnaptysBio (ANAB) versus Its PeersNovember 6, 2026 | americanbankingnews.comAnaptysBio (ANAB) Set to Release Quarterly Earnings on TuesdayNovember 2, 2026 | americanbankingnews.comSee More AnaptysBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AnaptysBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AnaptysBio and other key companies, straight to your email. Email Address About AnaptysBioAnaptysBio (NASDAQ:ANAB) is a biotechnology company focused on developing antibody-based treatments for inflammatory and autoimmune diseases. Its research programs target immune pathways that may be involved in conditions with significant unmet medical needs. The company’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 pathway, and ANB032, an investigational antibody targeting BTLA. AnaptysBio has also developed imsidolimab, an antibody targeting the IL-36 receptor; global rights to that program were licensed to Vanda Pharmaceuticals. Founded in 2005 and based in San Diego, California, AnaptysBio also has a history of licensing antibody-discovery programs to other pharmaceutical companies. Its work includes collaborations that have contributed to medicines developed and commercialized by partners.View AnaptysBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping3 Pharmaceutical Stocks That Offer Safety and GrowthKeeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCoreWeave's Backlog Is Surging—Can the Stock Follow?Can Constellation Energy's Contracts Power a Stock Rebound? Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
